

리스페리돈으로 인한 신경이완제 악성 증후군 1례

강화연 · 김용구[†] · 이민수

A Case of Risperidone-induced Neuroleptic Malignant Syndrome

Hwa-Yeon Kang, M.D., Yong-Ku Kim, M.D.Ph.D.,[†] Min Soo Lee, M.D.Ph.D.

ABSTRACT

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic reaction to neuroleptics, characterized by muscular rigidity, fever, autonomic dysfunction, and altered consciousness. The major theories to explain NMS is central dopaminergic blockade, but it is unclear. Risperidone is a new antipsychotic drug, a benzisoxazole derivative that blocks dopamine D₂ receptor and serotonin type 2 receptor. The comparatively greater serotonin-blocking activity is believed to give risperidone the specific property of not causing any more extrapyramidal side effects than conventional antipsychotics at the optimal dose of 4 - 8mg/day. It is postulated that risperidone is unlikely to cause NMS. Here, we report a case of risperidone induced neuroleptic malignant syndrome.

KEY WORDS : Risperidone · Neuroleptic malignant syndrome.

서론 (Neuroleptic malignant syndrome ; NMS) 0.02% 가 2 가 3.23% (Caroff 1980). NMS rus(1989) Levenson(1985) NMS CPK 가 NMS 가 (Roth 1986). Laza- 7 38 CPK가 가 myog- (Ito 1977 ; Grunhaus 1979 ; Levenson 1985). Risperidone NMS 10 creatine 가 (Lev - phosphokinase(CPK) 가] , 가 amazepine risperidone haloperidol carb -

Department of Psychiatry, College of Medicine, Korea university, Seoul, Korea

[†] : , 136 - 705 5가 126 - 1) (02) 920 - 5017, 920 - 5815,) (02) 927 - 2836

증례

1964

가 38.5 , 가 13,600 가
1996 (160/100mmHg), 가(130), 가(28),
가 , 1964 , Widal test
14
1972 , 15 가 ,
. “ 가 ”, “ 가
가 TV ”, “ 가
가 ”, “ 가
”
risperidone 9mg 16
10 (38.9), 18,600 가
19
CPK 686IU(22 269 IU), myoglobin 216.6
μg/L(90 μg/L) 가 , urine myog-
lobin , Widal test
7 T6 compressed fracture가 가 , 가
가
1996 7 19 risperidone . Ri-
speridone 2 21 (36.5),
(120/80mmHg), (76) 가 ,
WBC 8100 . , CPK 476 IU
, 가 1996 7 11 가 6 ,
, 9 CPK 176 IU, Myoglobin
57.32 μg/L . 10 clozapine
130/90mmHg, 36.5 , 84 , 20
5100 CPK가 385
IU/l (22 269 IU/l) 가
가
risperidone ,
haloperidol 45mg, carbamazepine 400mg,
benztropine 2mg, chlorpromazine 200mg, lorazepam 2mg
. Risperidone 2 hal-
operidol 36mg, carbamazepine 400mg, benztropine 2mg, ch-
lorpromazine 150mg, L - pam 2mg . 3
haloperidol 30mg, chlorpromazine 100mg
carbamazepine , 4 haloperidol
24mg, 5 18mg, 6 9mg , 6
chlorpromazine 50mg 7 6가 , , , , CPK 가, 가
haloperidol, chlorpromazine, lorazepam, benztropine
가
3 NMS (Hen-
10 risperidone . derson Wooten 1981). NMS D₂
Risperidone 2mg 3 6mg nigrostriatal pathway
. Risperidone 4 13 (Kaufmann Wyatt 1987).

고 찰

(peripheral vasomotor tone) .
 , reticular activating system (Akhtar Buckman 1977).
 NMS . Nisijima Ishiguro(1990)
 5 - hydroxyindoleacetic acid(5 - HIAA), homovanillic acid(HVA) 가 NMS
 가 . NMS
 가 haloperidol
 가 carbamazepine
 risperidone NMS가
 가 가
 , risperidone 4 NMS
 , risperidone NMS
 , NMS risperidone
 가 가
 Risperidone D₂
 5 - HT₂
 . Risperidone D₂
 5 - HT_{2A} 25 D₃,
 D₄, alpha₁, alpha₂ H₁
 , (Leyson 1994).
 5 - HT₂ 200 , D₂
 (Janssen 1988).
 risperidone NMS
 . risperidone
 가 D₂ 가 ,
 NMS가 가
 .
 clozapine
 NMS 가 10
 Clozapine D₁ D₂

, D₄ , 5 - HT₂, HT₁
 (Tsai 1995).
 , haloperidol, carbamazepine NMS
 가 가 . Haloperidol
 (cholinergic rebound) NMS가
 (Nisijima Ishiguro 1990)가 , carbamazepine
 carbamazepine 가 (Keepers 1990).
 NMS가 가 50%
 , carbamazepine halop -
 eridol 가 가 NMS가

결 론

Risperidone NMS 10
 halo -
 peridol carbamazepine risperidone
 NMS . Risperidone
 4 NMS , risperidone
 NMS . risperidone NMS
 가 가
 , NMS가

중심 단어 :

참고문헌

Akhtar S, Buckman J(1977) : The differential diagnosis of mutism : a review and report of 3 unusual cases. *Dis Nerv Sys* 38 : 558-563
Caroff SN(1980) : The neuroleptic malignant syndrome. *J Clin Psychiatry* 41 : 79-83
Keepers GA(1990) : Neuroleptic malignant syndrome associated with withdrawal from carbamazepine. *Am J Psychiatry* 147 : 1687
Grunhaus L, Sancovici S, Rimon R(1979) : Neuroleptic malignant syndrome due to depot fluphenazine. *J Clin Psychiatry* 40 : 99-100
Henderson VW, Wooten GF(1981) : Neuroleptic malignant syndrome : a pathogenetic role for dopamine receptor blockade? *Neurol* 31 : 132-137
Ito H, Ohtsuka N, Ogita K(1977) : Malignant neuroleptic syndrome : its present status in Japan and clinical problems. *Folia Psychiatr Neurol JPN* 31 : 565-576
Janssen PAJ, Niemegeers CJE, Awouters F, Schellenkens KHL, Megens AAHP, Meert TF(1988) : Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin S₂ and dopamine D₂ antagonistic properties. *J Pharmacol Exp Ther* 244 : 685-693

- Kaufmann CA, Wyatt RJ(1987)** : *Neuroleptic malignant syndrome. In : Psychopharmacology. 3rd ed, Meltzer HY, New York, Raven Press, pp1421-1430*
- Lazarus A, Mann SC, Caroff SM(1989)** : *The neuroleptic malignant syndrome and related conditions. Washington DC, American Psychiatric Press, pp3-56*
- Leyson JE, Janssen PMF, Megens AAHP, Schotte A(1994)** : *Risperidone : a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacological profile. J Clin Psychiatry 55 (suppl 5) : 5-12*
- Levenson JL(1985)** : *Neuroleptic malignant syndrome. Am J Psychiatry 142 : 1137-1145*
- Nisijima K, Ishiguro T(1990)** : *Neuroleptic malignant syndrome : a study of CSF monoamine metabolism. Biol Psychiatry 27 : 280-288*
- Roth SD, Addonizio G, Susman VL(1986)** : *Diagnosing and treating neuroleptic malignant syndrome. Am J Psychiatry 143 : 673*
- Tsai G, Crisostomo G, Rosenbalt ML, Stern TA(1995)** : *Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 7 : 91-95*